Conversations in Drug Development Trends

MARCH 7, 2024

When conducting first-in-human (FIH) clinical trials, small to midsize pharmaceutical and biotechnology companies are faced with several crucial choices that can shape the trajectory of their drug development pathway. For additional insights, download our full white paper, “ First-in-Human Studies: IND or CTA? ”.

Clinical Trials 52

Clinical Trials Trials FDA Drug Development 52

PerkinElmer

FEBRUARY 18, 2021

“To lead in product development and partner with customers in solving everyday challenges, we gather information regularly about current practices and future trends,” said Volker Eckelt, PhD, Senior Strategy Leader, PerkinElmer Life Sciences. A PerkinElmer White Paper offers a detailed look at the findings.

Biochemical Assays 52

Biochemical Assays Drugs Small Molecule Pharma Companies 52

The Pharma Data

DECEMBER 28, 2020

Our new directors are well-recognized for their leadership and accomplishments in the biopharmaceutical, biotechnology and pharmaceutical industries, as well as in public capital markets and corporate governance.” Mr. Weild is a globally recognized leader in capital formation and capital markets structure. from the Harvard T.H.

Pharmaceuticals 52

Pharmaceuticals Government Pharmaceutical Companies Therapies 52

The Pharma Data

SEPTEMBER 9, 2020

Receive expert-led insight from Dr. Heiner Oberkampf, Head of Data Governance at OSTHUS and learn how to: Digitally transform a drug development strategy. Transition to advanced analytics platforms to accelerate a product’s time-to-market.

Production 52

Production Laboratories Compliance Government 52

Conversations in Drug Development Trends

APRIL 4, 2024

Global Impact of ICH M10 Validation Guidelines Harmonization of bioanalytical validation methods is crucial in a world where pharmaceuticals are developed and approved across different regions. The ICH M10 guidelines aim to streamline this process, reducing redundancy in drug development and facilitating faster access to new therapies.

Small Molecule 80

Small Molecule Clinical Trials Pharmaceuticals Compliance 80

PPD

JUNE 17, 2024

Often, however, a hybrid use case will fit into one of these general categories: 1) An existing FSO arrangement needs additional expertise or resources to support a specific study function, requiring the developer to scale or augment that FSO arrangement with FSP services.

Clinical Trials 52

Clinical Trials Clinical Development Trials International 52

PPD

DECEMBER 19, 2023

As biotech and biopharma companies seek out the best solutions in increasingly competitive talent markets – and adapt to new demands, priorities and challenges – it’s important to remember that not all FSP/FSO providers are alike. Ready to fuel more efficient drug development?

International 52

International Research Pharmaceuticals Drug Development 52